Disc Presents Initial Data From Phase 2 BEACON Trial Of Bitopertin In Patients With Erythropoietic Protoporphyria At European Hematology Association 2023 Congress
Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin
Patients reported significant improvements in sunlight